Skip to content

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
  • Home
  • About
    • NIH Collaboratory
      • Coordinating Center
      • NIH Collaboratory Trials
      • Core Working Groups
      • Steering Committee
      • Distributed Research Network
      • Our Impact
    • Living Textbook
      • Table of Contents
      • How to Use This Site
  • Resources
    • Data and Resource Sharing
    • Training Resources
    • Tools for Researchers
    • Publications
    • Knowledge Repository
  • Webinar
  • Podcast
  • News
    • News Feed
    • Calendar
    • Subscribe
return to home
Subscribe to Newsletter go to twitter feed go to linkedin go to blue sky feed
Search
NIH Collaboratory
Living Textbook of
Pragmatic Clinical Trials

COVID-19 Resources

Access the latest information on COVID-19 for clinical researchers
home button

Rethinking Clinical Trials

A Living Textbook of Pragmatic Clinical Trials

  • Design
    • What is a Pragmatic Clinical Trial?
    • Decentralized Pragmatic Clinical Trials
    • Developing a Compelling Grant Application
    • Experimental Designs and Randomization Schemes
    • Endpoints and Outcomes
    • Analysis Plan
    • Using Electronic Health Record Data
    • Building Partnerships and Teams to Ensure a Successful Trial
    • Intervention Delivery and Complexity
    • Patient Engagement
  • Data, Tools & Conduct
    • Assessing Feasibility
    • Acquiring Real-World Data
    • Assessing Fitness-for-Use of Real-World Data
    • Study Startup
    • Participant Recruitment
    • Monitoring Intervention Fidelity and Adaptations
    • Patient-Reported Outcomes
    • Clinical Decision Support
    • Mobile Health
    • Electronic Health Records–Based Phenotyping
    • Navigating the Unknown
  • Dissemination & Implementation
    • Data Sharing and Embedded Research
    • Dissemination Approaches for Different Audiences
    • Implementation
    • End-of-Trial Decision-Making
  • Ethics & Regulatory
    • Privacy Considerations
    • Identifying Those Engaged in Research
    • Collateral Findings
    • Consent, Disclosure, and Non-Disclosure
    • Data and Safety Monitoring
    • Ethical Considerations of Data Sharing in Pragmatic Clinical Trials
    • Ethics for AI and ML
    • IRB Responsibilities and Procedures

Additional Protections: Certificates of Confidentiality

CHAPTER SECTIONS

Privacy Considerations


Section 3

Additional Protections: Certificates of Confidentiality

Expand Contributors

Stephanie Morain, PhD
Judith Carrithers, JD
Joseph Ali, JD
Vasiliki Nataly Rahimzadeh, PhD

Contributing Editor

Karen Staman, MS
Damon M. Seils, MA

Certificates of confidentiality are intended to protect research data from use in civil or criminal matters. They are intended to cover research that could be sensitive or stigmatizing or could result in civil or criminal liability (Sugarman and Carrithers 2021). As part of the 21st Century Cures Act, certificates of confidentiality are automatically issued for all biomedical, behavioral, clinical, and other research that "collects or uses identifiable sensitive information" and is funded wholly or in part by the NIH. Under this act, data are considered identifiable if "there is at least a very small risk" of reidentification, including as a result of combining that information with other available data sources. The automatic issuance of certificates of confidentiality creates unexpected complications for pragmatic trials (Sugarman and Carrithers 2021), which are briefly described here.

Pragmatic clinical trials embedded in healthcare systems raise the following data privacy and data protection issues relevant to certificates of confidentiality:

  • Use of sensitive or otherwise stigmatizing data for research when the data are mined from the EHR without patient knowledge
  • Opaque requirements for notifying patients about the provisions of the certificate of confidentiality

It remains unclear under the disclosure requirements for certificates of confidentiality whether researchers are permitted to include identifiable research data in the EHR and subsequently to allow disclosure of those data outside the research context without consent. The NIH provides some guidance on the provisions:

The policies for handling research data and medical records can differ with each institution. For this reason, NIH suggests that investigators who intend to include research data in subjects' medical records work with their own institutional counsel and IRB to ensure that all documents are handled appropriately and in line with the institution's own policies.

However, formal guidance on the policy as it pertains to pragmatic trials is still needed.

Previous Section Next Section

SECTIONS

CHAPTER SECTIONS

sections

  1. Introduction
  2. Current Federal Regulatory Framework: Common Rule, FDA, and HIPAA
  3. Additional Protections: Certificates of Confidentiality
  4. Individual Privacy
  5. Clinician and Institutional Privacy Considerations

Resources

New and Improved? 21st Century Cures Act Revisions to Certificates of Confidentiality
An article providing information about certificates of confidentiality under the 21st Century Cures Act.

Responding to Signals of Mental and Behavioral Health Risk in Pragmatic Clinical Trials: Ethical Obligations in a Healthcare Ecosystem
An article describing challenges, including privacy-related challenges, of monitoring and responding to signals of potential distress in pragmatic clinical trials.

Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule

Privacy and Confidentiality in Pragmatic Clinical Trials; Rethinking Clinical Trials Grand Rounds; August 19, 2016

REFERENCES

back to top

Sugarman J, Carrithers J. 2021. Certificates of confidentiality and unexpected complications for pragmatic clinical trials. Learn Health Sys. 5. doi:10.1002/lrh2.10238. PMID: 33889738.

back to top


Version History

July 3, 2025: Made nonsubstantive changes to the text and updated links as part of the regular content review (changes made by D. Seils).

Published September 27, 2022

current section :

Additional Protections: Certificates of Confidentiality

  1. Introduction
  2. Current Federal Regulatory Framework: Common Rule, FDA, and HIPAA
  3. Additional Protections: Certificates of Confidentiality
  4. Individual Privacy
  5. Clinician and Institutional Privacy Considerations

Citation:

Morain S, Carrithers J, Ali J, et al. Privacy Considerations: Additional Protections: Certificates of Confidentiality. In: Rethinking Clinical Trials: A Living Textbook of Pragmatic Clinical Trials. Bethesda, MD: NIH Pragmatic Trials Collaboratory. Available at: https://rethinkingclinicaltrials.org/chapters/ethics-and-regulatory/special-privacy-considerations/additional-protections-certificates-of-confidentiality/. Updated July 3, 2025. DOI: 10.28929/172.

Footer Menu

  • How to Use This Site
  • About NIH Collaboratory
  • Enrollment Reporting
  • Grand Rounds
  • Funding Statement
Link to Twitter Link to LinkedIn Link to Blue Sky Link to NIH Collaboratory email

Reference in this Web site to any specific commercial products, process, service, manufacturer, or company does not constitute its endorsement or recommendation by the U.S. Government or National Institutes of Health (NIH). NIH is not responsible for the contents of any “off-site” Web page referenced from this server.

Log in
Privacy Statement
WordPress is a content management system and should not be used to upload any PHI as it is not an environment for which we exercise oversight, meaning you the author are responsible for the content you post. Please use this system accordingly. Site Map